Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 6, 2020February 6, 2020

Follicular Lymphoma Patients in Remission for at Least 2 Years May Be Cured, Study Suggests

News

People with follicular lymphoma who are in remission for at least two years following treatment may no longer show detectable signs of the disease or possibly be cured. That ... Read more

January 30, 2020January 30, 2020

Imbruvica Plus Rituximab Prolongs Survival in Untreated CLL/SLL Patients, Phase 3 Trial Finds

News

Imbruvica (ibrutinib) in combination with rituximab continues to prolong survival and the time without disease progression in previously untreated adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma ... Read more

November 19, 2019November 19, 2019

FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at ... Read more

November 12, 2019

Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL

News

Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people ... Read more

August 1, 2019

Allergan Issues Worldwide Recall of Some Breast Implant Products Due to Lymphoma Risk

News

Allergan has issued a worldwide recall of its BIOCELL textured breast implant products, due to the potential risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The recall — for Allergan’s ... Read more

July 2, 2019July 2, 2019

CHMP Recommends Expanding Imbruvica Use in the EU to Include 2 New Cancer Regimens

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to ... Read more

June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. ... Read more

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b ... Read more

June 13, 2019June 20, 2019

FDA Gives OK to Polivy plus Rituxan-Bendamustine Combo to Treat Advanced DLBCL

News

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq), used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed ... Read more

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, ... Read more

Pin It on Pinterest